FalckKGrohnPSorsaMet al.Mutagenicity in urine of nurses handling cytostatic drugs. Lancet1979; 1: 1250–1251.
2.
International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP Standards of Practice. Safe handling of cytotoxics. J Onc Pharm Pract2007; 13: 1–81.
3.
SessinkPJMBoerKAScheefhalsAPHet al.Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health1992; 64: 105–112.
4.
ConnorTHAndersonRWSessinkPJMet al.Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm1999; 56: 1427–1432.
5.
SessinkPJMRolfMERydenNS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm1999; 34: 1311–1317.
6.
ConnorTHAndersonRWSessinkPJet al.Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm2002; 59: 68–72.
7.
SpiveySConnorT. Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm2003; 38: 135–139.
8.
WickCSlawsonMHJorgensonJAet al.Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314–2320.
9.
HarrisonBRPetersBGBingMR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system transfer device versus standard preparation techniques. Am J Health Syst Pharm2006; 63: 1736–1744.
10.
NymanHJorgensonJSlawsonMH. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system transfer device. Hosp Pharm2007; 42: 219–225.
11.
SessinkPJMConnorTHJorgensonJAet al.Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract2011; 17: 39–48.
12.
FavierBLabrosseHGilles-Afchainet al.The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation. J Oncol Pharm Pract2012; 18: 37–45.
13.
ClarkBASessinkPJ. Use of a closed system drug-transfer device. J Oncol Pharm Pract2013; 19: 99–104.
14.
SessinkPJMTrahanJCoyneJW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm2013; 48: 204–2012.
15.
SimonNVasseurMPinturaudMet al.Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PloS ONE2016; 11: e0159052–e0159052.
16.
National Institute for Occupational Safety and Health. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care setting. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. Washington, DC: US Department of Health and Human Services.
17.
De PrijckKD’HaeseEVandenbrouckeJet al.Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Lett Appl Microbiol2008; 47: 543–548.
18.
McMichaelDMJeffersonDMCareyETet al.Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits2001; 3: 9–16.
19.
CareyETForreyRAHaughsDet al.Second look at utilization of a closed-system transfer device (PhaSeal). Am J Pharm Benefits2001; 3: 311–318.
20.
RoweECSavageSWRutalaWAet al.Economic and microbiological evaluation of a single-dose vial extension for hazardous drugs. J Oncol Pract2012; 8: e45–e49.
21.
HoKVEdwardsMSSolimandoDAJret al.Determination of extended sterility for single-use vials using the PhaSeal closed-system transfer device. J Hemat Oncol Pharm2016; 6: 46–50.
22.
Pharmaceutical compounding – sterile preparations (general information chapter 797). In: The United States Pharmacopeia, 34th rev., and the National Formulary, 29th ed. Rockville, MD: United States Pharmacopeial Convention; 2011, pp.336–373.
23.
EdwardsMSSolimandoDAJrGrollmanFRet al.Cost savings realized by use of the PhaSeal® closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract2013; 19: 338–347.
24.
VandenbrouckeJRobaysH. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. EJHP Pract2008; 14: 37–42.
25.
SmithRSV. A 2-year retrospective review of vial sharing options for the compounding of cytotoxics. Eur J Hosp Pharm2015; 22: 161–164.
26.
JuhaszABatkaGSzucsA. Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs Ther Perspect2016; 32: 170–176.
27.
GilbarPJChambersCRGilbarEC. Opportunities to significant reduce expenditure associated with cancer drugs. Future Oncol2017; 13: 1311–1322.
28.
SiddiquiMRajkumarSV. The high cost of cancer drugs and what we can do about it. Mayo Clic Proc2012; 87: 935–943.
29.
PrasadVDe JesusKMailankodyS. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol2017; 14: 381–390.
30.
BachPBContiRMMullerRJet al.Overspending driven by oversized single dose vials of cancer drugs. BMJ2016; 352: i788–i788.
31.
Gilbar PJ and Chambers CR. How can we ensure value for money from expenditure on injectable cancer drugs? J Oncol Pharm Pract. Epub ahead of print 29 April 2017. DOI: 10.1177/1078155217706195.
32.
GatesmanMLSmithTJ. The shortage of essential chemotherapy drugs in the United States. New Engl J Med2011; 365: 1653–1655.
33.
BeckerDJTalwarSLevyBPet al.Impact of oncology drug shortages on patient therapy: unplanned treatment changes. J Oncol Pract2013; 9: e122–128.
34.
McBrideAHolleLMWestendorfCet al.National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm2013; 70: 609–617.
35.
BautersTClausBOMNorgaKet al.Chemotherapy drug shortages in paediatric oncology: a 14-year single-centre experience in Belgium. J Oncol Pharm Pract2016; 22: 766–770.
36.
LienKCheungMCChanKKW. Adjusting for drug wastage in economic valuations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract2016; 12: e369–379.
